Diasome raises $30M in series A round

Metabolic play Diasome Pharmaceuticals Inc. (Cleveland, Ohio) said it raised up to $30 million in a tranched series A round led by Medicxi. Also participating were the JDRF T1D Fund, Black Beret Life Sciences and an investor group led by McDonald Partners.

The company is developing a formulation of insulin with proprietary liver-targeting molecules called Hepatocyte Directed Vesicles (HDV). CEO Robert Geho told BioCentury that an early incarnation of Diasome focused on oral insulin, but the company was relaunched in 2012 to develop injectable insulin products...